ABL Bio Inc (298380)

Currency in KRW
66,800
+6,000(+9.87%)
Closed·
Advertisement
298380 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
62,20068,900
52 wk Range
59,800257,500
Key Statistics
Bid/Ask
66,800.00 / 66,900.00
Prev. Close
60,800
Open
63,200
Day's Range
62,200-68,900
52 wk Range
59,800-257,500
Volume
334.5K
Average Volume (3m)
441.98K
1-Year Change
-4.8433%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
298380 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
257,500
Upside
+285.48%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

ABL Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 257,500
(+285.48% Upside)

Earnings

Latest Release
08/05/2026
EPS / Forecast
-260.86 / -150.21
Revenue / Forecast
13.14B / --
EPS Revisions
Last 90 days

ABL Bio (298380) Income Statement & Profits

Compare 298380 to Peers and Sector

Metrics to compare
298380
Peers
Sector
Relationship
P/E Ratio
−155.0x−17.4x−0.3x
PEG Ratio
−2.23−0.300.00
Price/Book
20.7x2.1x2.6x
Price / LTM Sales
41.4x6.8x3.0x
Upside (Analyst Target)
289.2%51.8%56.7%
Fair Value Upside
Unlock17.2%9.4%Unlock

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.01M7.16%267.82B
Other Institutional Investors
4.45M7.95%297.16B
Public Companies & Retail Investors
47.53M84.89%3.17T
Total
55.99M100.00%3.74T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
National Pension Service3.97%2,224,087148,569,012
The National Pension Fund3.97%2,224,087148,569,012

People Also Watch

333,500
128940
+7.06%
97,600
240810
+27.92%
2,417,000
298040
+27.61%
183,800
108490
+16.04%
184,800
010120
+22.95%

FAQ

What Is the ABL Bio (KOSDAQ: 298380) Share Price Today?

The ABL Bio stock price today is 66,800 KRW.

What Stock Exchange Does ABL Bio (298380) Trade On?

ABL Bio is listed and trades on the KOSDAQ.

What Is the Ticker (Stock Symbol) for ABL Bio?

The stock symbol (also called a 'ticker') for ABL Bio is "298380."

What Is the Current ABL Bio Market Capitalisation?

As of today, ABL Bio (KOSDAQ: 298380) market cap is 3.74T KRW.

What Is ABL Bio's (298380) Earnings Per Share (TTM)?

The ABL Bio EPS is currently -453 (Trailing Twelve Months).

Is 298380 a Buy or Sell From a Technical Analyst Perspective?

Based on today's ABL Bio moving averages and other technical indicators, the daily buy/sell signal for 298380 stock is Strong Sell.

How Many Times Has ABL Bio Stock Split?

ABL Bio has split 0 times. (See the 298380 stock split history page for full effective split date and price information.)

How Many Employees Does ABL Bio Have?

ABL Bio has 102 employees, based on their latest Companies House report.

What is the current trading status of ABL Bio (KOSDAQ: 298380)?

As of 01/08/2026, ABL Bio (298380) is trading at a share price of 66,800 KRW, with a previous close of 60,800 KRW. The stock has fluctuated within a day range of 62,200 KRW to 68,900 KRW, while its 52-week range spans from 59,800 KRW to 257,500 KRW.

What Is ABL Bio (298380) Price Target According to Analysts?

The average 12-month price target for ABL Bio is 257,500 KRW, with a high estimate of 280000 KRW and a low estimate of 230000 KRW. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +285.48% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.